Related references
Note: Only part of the references are listed.Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
John D. Powderly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014
Lia C. Scott et al.
CANCER (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
Maxine Bauzon et al.
ONCOIMMUNOLOGY (2019)
METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
L. T. Vahdat et al.
CANCER RESEARCH (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
Gentry T. King et al.
INVESTIGATIONAL NEW DRUGS (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Peixin Dong et al.
FRONTIERS IN ONCOLOGY (2018)
Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor
Anthony T. Cao et al.
CANCER RESEARCH (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Joseph D. Khoury et al.
CLINICAL CANCER RESEARCH (2018)
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
Xiaoxian Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Synthetic lethality and cancer
Nigel J. O'Neil et al.
NATURE REVIEWS GENETICS (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression
K. Roarty et al.
ONCOGENE (2017)
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
Neelima Vidula et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Allyson J. Ocean et al.
CANCER (2017)
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2017)
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
X. Pivot et al.
ANNALS OF ONCOLOGY (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database
Magdalena L. Plasilova et al.
MEDICINE (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
Carlos Alberto Gomez-Roca et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Robert M. Sharkey et al.
CLINICAL CANCER RESEARCH (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
Django Sussman et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Upregulation of Trop-2 quantitatively stimulates human cancer growth
M. Trerotola et al.
ONCOGENE (2013)
The Trop-2 signalling network in cancer growth
E. Guerra et al.
ONCOGENE (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling
Hui-Wen Lue et al.
PLOS ONE (2011)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
Carol A. Parise et al.
BREAST JOURNAL (2009)
The epidemiology of triple-negative breast cancer, including race
Katrina F. Trivers et al.
CANCER CAUSES & CONTROL (2009)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of dolastatin-10 in patients with advanced breast cancer
EA Perez et al.
INVESTIGATIONAL NEW DRUGS (2005)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer
S Yamashita et al.
NATURE (2004)
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
FJ Esteva et al.
CANCER (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Share Paper
